Compliance to clinical guidelines for early-stage epithelial ovarian cancer in relation to patient outcome

被引:18
作者
Sijmons, Edith A.
van Lankveld, Marieke A. L.
Witteveen, Petronella O.
Peeters, Petra H. M.
Koot, Veronica C. M.
van Leeuwen, Jules Schagen
机构
[1] St Antonius Hosp, Dept Gynaecol, NL-3430 EM Nieuwegein, Netherlands
[2] Univ Utrecht, Med Ctr, Dept Gynaecol, NL-3508 GA Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[4] Univ Utrecht, Med Ctr, Dept Internal Med, NL-3508 GA Utrecht, Netherlands
[5] Comprehens Canc Ctr Middle Netherlands, NL-3501 DB Utrecht, Netherlands
关键词
early-stage ovarian neoplasms; surgical staging; guideline adherence; survival;
D O I
10.1016/j.ejogrb.2006.03.014
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: To assess compliance to current surgical staging and adjuvant treatment guidelines for patients with early-stage epithelial ovarian carcinoma and its impact on overall survival. Methods: Patients diagnosed between 1991 and 1997 with early-stage ovarian cancer were recruited from the Regional Cancer Registry of the central region in the Netherlands. Demographic data, tumour characteristics, surgical findings and therapeutic data were abstracted from medical records. Patients were classified into optimal and non-optimal surgical staging. Overall survival was estimated using Kaplan-Meier method. To adjust for age hazard ratios for overall survival were estimated with a Cox Proportional Hazards model. Results: One hundred and twenty-five patients were included in the study, 41 of them (32.8%) were optimally staged. Guidelines for adjuvant radio- or chemotherapy were adequately followed in all 62 grade I patients and in 44 out of 59 grade II and III patients (74.6%). During 734.6 person-years of follow up 31 patients died. Five-year overall survival figures were 97.6% in the optimally staged group and 68.5% in the non-optimally staged group. Patients who were non-optimally staged, had a significant higher risk to die than those who were optimally staged (HR: 7.4: 95% CI: 1.7-32.2). In patients with a grade II and III tumours, complete surgical staging still had a significant influence on survival (HR: 3.8: 95% CI 1.7-8.3). In women with grade II or III tumours, adjuvant radio- or chemotherapy administered in accordance to the guidelines did not improve overall survival regardless whether they were optimally staged or not. Conclusion: Incomplete staging in early-stage ovarian cancer leads to gross mis-classification in grade II and III tumours and to a lesser extent in grade I tumours. This leads to undertreatment in both surgical and adjuvant therapy. Subsequently unnecessary deaths may occur. More effort must be put in identifying obstacles interfering with compliance of guidelines (c) 2006 Published by Elsevier Ireland Ltd.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 17 条
[1]  
[Anonymous], INT CLASS DIS ONC
[2]   ANATOMICAL AND PATHOLOGICAL-STUDY OF RETROPERITONEAL NODES IN EPITHELIAL OVARIAN-CANCER [J].
BENEDETTIPANICI, P ;
GREGGI, S ;
MANESCHI, F ;
SCAMBIA, G ;
AMOROSO, M ;
RABITTI, C ;
MANCUSO, S .
GYNECOLOGIC ONCOLOGY, 1993, 51 (02) :150-154
[3]  
Colombo N, 2003, J NATL CANCER I, V95, P125
[4]  
DEMBO AJ, 1983, CLIN OBSTET GYNAECOL, V10, P261
[5]   PELVIC AND PARA-AORTIC LYMPHADENECTOMY IN CANCER OF THE OVARY [J].
DIRE, F ;
FONTANELLI, R ;
RASPAGLIESI, F ;
DIRE, E .
BAILLIERES CLINICAL OBSTETRICS AND GYNAECOLOGY, 1989, 3 (01) :131-142
[6]  
EINHORN N, 1980, NORDISK OBSTET GYNEK, V2, P65
[7]  
Faught W., 1996, European Journal of Gynaecological Oncology, V17, P200
[8]   SURGICAL STAGING AND CYTOREDUCTIVE SURGERY OF EPITHELIAL OVARIAN-CANCER [J].
HOSKINS, WJ .
CANCER, 1993, 71 (04) :1534-1540
[9]   Clinically apparent early stage invasive epithelial ovarian carcinoma: Should all be treated similarly? [J].
Le, T ;
Krepart, GV ;
Lotocki, RJ ;
Heywood, MS .
GYNECOLOGIC ONCOLOGY, 1999, 74 (02) :252-254
[10]   The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma [J].
Lee, T ;
Adolph, A ;
Krepart, GV ;
Lotocki, R ;
Heywood, MS .
GYNECOLOGIC ONCOLOGY, 2002, 85 (02) :351-355